Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension
American Journal of Hypertension · 15.09.2023 · 36 (10) · 561-567
DOI: 10.1093/ajh/hpad055 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hypertension, online erschienen am 21.06.2023. Verfasst von Hongyi Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hypertension, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Hypertension. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Shenzhen Salubris Pharmaceuticals Co., Ltd..
Abstract (Originalsprache)
BACKGROUND Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension (EH). METHODS Patients with mild-to-moderate EH, selected at 44 sites in China from September 9, 2016, to December 7, 2018, were administered 240 mg allisartan isoproxil daily for 4 weeks. Patients with controlled blood pressure (BP) continued monotherapy for 8 weeks, others were randomly assigned (1:1) to A + D group (allisartan isoproxil 240 mg + indapamide 1.5 mg) or A + C group (allisartan isoproxil + amlodipine besylate 5 mg) for 8 weeks. BP were measured at week 4, 8 and 12. RESULTS 2,126 patients were included in the analysis. After 12 weeks of treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased by 19.24 ± 12.02 and 10.63 ± 8.89 mm Hg, respectively, and the overall BP control rate was 78.56%. The sitting blood pressures (SBP/DBP) decreased by 19.12 ± 11.71/10.84 ± 8.73 mm Hg in patients with 12 weeks allisartan isoproxil monotherapy (both P < 0.0001). The BP reductions and control rates were comparable between A + D and A + C groups. 48 patients with monotherapy-controlled BP underwent ambulatory BP monitoring, with a mean decrease in ambulatory BP of 10.04 ± 10.87/5.50 ± 8.07 mm Hg after 12 weeks of treatment, and consistent reductions between day and night. SBP and DBP had trough-to-peak ratios of 64.64% and 62.63% and smoothness indices of 3.82 and 2.92, respectively. CONCLUSIONS An allisartan isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH. PROJECT REGISTRATION NO CTR20160138 (Registration and Information Disclosure Platform for China Drug Clinical Studies, http://www.chinadrugtrials.org.cn/index.html).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hypertension, Peking University People's Hospital, Beijing, China.
ORCID-Profile: Ningling Sun
Förderung
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Zitieren
APA
Wang, H., Xi, Y., Chen, Y., Wang, L., Yang, F., Lu, X., & Sun, N. (2023). Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension. American Journal of Hypertension, 36(10), 561-567. https://doi.org/10.1093/ajh/hpad055
Vancouver
Wang H, Xi Y, Chen Y, Wang L, Yang F, Lu X, et al. Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension. American Journal of Hypertension. 2023;36(10):561-567. doi:10.1093/ajh/hpad055
BibTeX
@article{Wang2023,
author = {Wang, Hongyi and Xi, Yang and Chen, Yuanyuan and Wang, Luyan and Yang, Fan and Lu, Xining and Sun, Ningling},
title = {Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension},
journal = {American Journal of Hypertension},
year = {2023},
volume = {36},
number = {10},
pages = {561--567},
doi = {10.1093/ajh/hpad055}
}
EUVIMED